NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,417−0.18%BTC$81,133−0.12%VIX14.81−4.08%live tape · as of 23:00 UTC · 20 Sep
The Screen · Healthcare · Medical Instruments & Supplies
Solventum
SOLV · a US exchange · USD · Market cap $14.9B · 20,584 employees
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.
FAIL · Does not pass the screen
87.65 USD
At the last full screen 2026-09-10
Screened 2026-09-10 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 87.65 against the desk's fair-value range, base estimate 81.97, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price87.65 USD
Fair value81.97
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-09-13Read Accumulation87.65+0.0% to today ✓
2026-08-13Read Markup82.96+5.7% to today ✓
2026-07-02Read Accumulation81.01+8.2% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Solventum holds its Markdown at $87.65. The statistical read favours the buyers, held for 27 days.
As held on the ledger · 2026-09-10
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 27 days
Price at the screen
$87.65
Valuation
10.72 trailing · 12.13 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.69
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
35.22%
Below 33%
Interest-bearing debt is 35.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
13.38%
Below 49%
Money owed to the company is 13.4% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades above our $81.97 fair value estimate, moderate competitive moat, 2.20% revenue growth.
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. The price runs 6.5% above the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +8% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Solventum fails debt test despite solid margins
Picture a hospital supplier whose kits keep operations running, yet the balance sheet carries more debt than the business can comfortably carry. We pass on Solventum because the shares sit 8 percent above our fair value and the ethical screen flags excessive leverage straight away.
Revenue is already shrinking 3 percent, the forward multiple of 11.5 times offers little cushion for that decline, and the 35 percent return on equity looks less impressive once the debt load is considered. A moderate moat and 17 percent profit margin do not offset the valuation gap or the red flag on the balance sheet.
Thirteen analysts may still lean buy with an 85 dollar median target, yet that consensus ignores both the cyclical pressure on healthcare spending and the leverage that tripped our screen. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SOLV trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $94.
2026-08-13Markup · changed$82.96+2.4%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $82.
2026-07-18Accumulation$81.01+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $82.
2026-07-03Accumulation$81.01+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$81.01Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
